GLP-1 Tirzepatide & B6 30mg (10mg/1mL)

Route: Subcutaneous injection. Administer into the abdomen, thigh, or upper arm; rotate injection sites weekly. This multi-dose vial (3 mL total at 10 mg/mL) is typically used for once-weekly dosing. Do not inject into irritated, bruised, or scarred skin. Each injection should use a new, sterile needle.

Dosing is prescriber-determined. This 30 mg vial supports multiple weekly doses (e.g., three 10 mg doses) or a single higher dose per prescriber protocol:

• Once-weekly subcutaneous injection; consistent dosing day is recommended.
• Dose escalation should be gradual, based on tolerability and clinical response.
• Prescriber determines the specific per-injection volume and frequency.

• Tirzepatide: Simultaneously activates GIP receptors (potentiating insulin secretion and lipid metabolism) and GLP-1 receptors (augmenting glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and activating hypothalamic satiety centers).
• Pyridoxine (B6): Cofactor in synthesis of serotonin, dopamine, and GABA; may attenuate the central nausea pathways stimulated by GLP-1 receptor agonism at the brainstem area postrema.

This preparation is used prescriber-directed for patient-specific management of type 2 diabetes or obesity-related comorbidities. The 30 mg vial (10 mg/mL) is suited for patients at the 10 mg weekly maintenance dose requiring a multi-week supply in a single vial, or for practices managing multiple dosing sessions.

Monitoring: HbA1c, fasting glucose, renal function, thyroid history review, injection site assessment, and pancreatitis vigilance as with all GLP-1/GIP receptor co-agonist therapy.

Contraindications:

• Personal or family history of medullary thyroid carcinoma or MEN2.
• Known hypersensitivity to tirzepatide or formulation components.

Warnings & Precautions:

• Thyroid C-cell tumor risk (class warning); pancreatitis; hypoglycemia with concomitant insulin or secretagogues; acute kidney injury from dehydration; GI motility concerns.
• Multi-dose vials require sterile technique with each access to prevent contamination.

Drug Interactions:

• Delayed gastric emptying may alter oral drug absorption; monitor narrow-therapeutic-index medications.
• Additive hypoglycemia with insulin and sulfonylureas.

Common Side Effects: Nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions, decreased appetite.

Refrigerate at 2°C–8°C. Protect from light. Do not freeze. After first use, store refrigerated and use within the beyond-use date assigned by Genesis Compounding. Each access must use a new sterile needle and aseptic technique. Discard any unused portion after the beyond-use date.

How many doses does this vial contain?

At 10 mg/mL with a total of 30 mg, this vial contains three 1 mL (10 mg) doses, suitable for three once-weekly injections. Your prescriber will specify exact volumes per dose.

Why is B6 added to the tirzepatide injection?

Pyridoxine (B6) is included to help support tolerability. Nausea is one of the most common side effects of tirzepatide; B6 has well-documented antiemetic properties and may reduce GLP-1-associated GI discomfort by supporting serotonin and GABA synthesis.

Is this an FDA-approved product?

No. This is a compounded preparation prepared by Genesis Compounding as a patient-specific, prescriber-directed 503A product and is not FDA-approved as a compounded drug.

What if I miss a weekly dose?

If a dose is missed, administer it as soon as possible if there are at least 3 days before the next scheduled dose. If fewer than 3 days remain, skip the missed dose. Do not double doses. Contact your prescriber with questions about missed doses.

How do I prevent injection site reactions?

Rotate injection sites with each weekly dose (abdomen, thigh, upper arm) and allow previous sites to recover. Avoid areas of active irritation, redness, or bruising. Let the solution reach room temperature briefly before injecting for comfort.